Meeting
2011 ASCO Annual Meeting
Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer.
Authors
N. T. Brewer
University of North Carolina Gillings School of Public Health, Chapel Hill, NC
N. T. Brewer , C. M. Walko , W. K. Chiu , L. G. Dressler , A. Yuen , P. Rubin , O. A. Olajide , S. G. Moore , R. E. Raab , D. R. Carrizosa , S. W. Corso , G. Schwartz , J. M. Peppercorn , H. L. McLeod , L. A. Carey , W. J. Irvin Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Health Services Research
Track
Health Services Research
Sub Track
Health Services Research
Clinical Trial Registration Number
NCT00764322
Citation
J Clin Oncol 29: 2011 (suppl; abstr 6029)
Abstract #
6029
Poster Bd #
18
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Simplified CYP2D6 metabolizer phenotype categorization of patients treated with tamoxifen: Role for endoxifen level monitoring?
First Author: Clara Inkyung Lee
Poster
2012 ASCO Annual Meeting
CYP2D6 genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen.
First Author: Bavanthi Balakrishnar
Poster
2011 ASCO Annual Meeting
The effect of a tamoxifen dose increase from 20 mg to 40 mg in patients with at least one inactive CYP2D6 variant allele and/or concomitant use of a CYP2D6 inhibitor.
First Author: M. E. B. Welzen
Poster
2018 ASCO Annual Meeting
A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen.
First Author: Anabel Beatriz Sanchez-Spitman